RxDoctor Payments Data

Arshad Anwar, MD

Internal Medicine · Brooklyn, NYNPI 1174635916

Payments from drug & device makers

$2,206in general payments, 2019–2025

Across 46 payments — averaging $47.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$575
  • AstraZeneca$380
  • Philips North America LLC$339
  • AbbVie$235
  • Abbott$189
  • Boehringer Ingelheim$119
  • plus $368 from 10 others

What the payments were for

  • Food & beverage$2,18699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,206 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$55,620
Medicare patients
123
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin456$365,801
JanumetSitagliptin Phos/Metformin Hcl452$350,423
FarxigaDapagliflozin Propanediol378$293,381
Diclofenac Sodium452$172,284
TrulicityDulaglutide130$157,989
OzempicSemaglutide151$154,382
VascepaIcosapent Ethyl347$118,997
JanuviaSitagliptin Phosphate115$101,036
EliquisApixaban85$71,615
MounjaroTirzepatide63$70,329
CreonLipase/Protease/Amylase63$69,838
JentaduetoLinagliptin/Metformin Hcl100$67,555
RayosPrednisone13$67,217
TradjentaLinagliptin75$64,996
LinzessLinaclotide105$61,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto, Tradjenta, Trijardy Xr$119$516,648653 claims
MerckJanumet, Januvia$45$451,459567 claims
AstraZenecaFarxiga, Brilinta, Symbicort$380$346,235503 claims
Lilly USA, LLCTrulicity, Mounjaro$20$228,318193 claims
Novo NordiskOzempic, Rybelsus$48$206,343204 claims
AbbVieCreon, Linzess, Ubrelvy$235$151,046180 claims
GSKBreo Ellipta, Incruse Ellipta, Shingrix, Anoro Ellipta$575$97,414240 claims
PfizerEliquis$20$71,61585 claims
GileadViread$78$34,44627 claims
NovartisEntresto$18$20,42723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →